ClinicalTrials.gg
CompletedNCT07940608PUDDINGUpdated Nov 17, 2026

Pilot Study of an Educational Tool for Chronic Obstructive Pulmonary Disease

An interventional study of Guidance of the treating physician by a digital tool in Chronic Obstr Lung Disease, sponsored by Prima Vard AB. Completed at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Prima Vard AB · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Mar 2026, registered Nov 2026).
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden — 16 open to participants now, 24 under way, 6 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sweden.

Enrollment
117th of 123
25 · median 229
Started
2026
with 3 others
No phase
35 of 152
6 open now
Registered
152nd of 152
by date

Among the 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden, this one is the 117th largest by enrollment of the 123 interventional ones that give a count, is one of 4 that started in 2026, is one of 35 with no phase, and was the 152nd registered.

Pulmonary Disease, Chronic Obstructive

5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

16 of the 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Pulmonary Disease, Chronic Obstructive with a site in Sweden, or all of them as a file.
02

Study summary

The inadequate fulfillment of national targets for COPD described above indicates that interventions designed to increase adherence to recommendations in established guidelines could improve patient outcomes. This pilot study is therefore intended to indicate if a digital educational tool can increase adherence to COPD guidelines and measurably improve measures of disease control. If the objectives of the study are met, it provides a rationale for further developing the tool and validating it in controlled studies. This is an 8-week, single-arm pilot study in patients with COPD. A total of 35 patients will be included. Based on an anticipated screening failure rate of 50%, 70 patients will be screened. Patients will receive standard of care with a board-certified physician using an educational COPD tool.

03

Conditions studied

  • Chronic Obstr Lung Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed at least 6 months prior to inclusion
  • mMRC score of 2 or more at screening visit

Exclusion criteria

Exclusion Criteria:

  • Previous participation in this study. Participation is defined as .
  • Currently participating in clinical trials for .
  • Ongoing oxygen treatment.
  • Significant pulmonary disease other than COPD (e.g., asthma, lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchiectasis, or Churg-Strauss syndrome, etc.).
  • History of or planned pneumonectomy or lung volume reduction surgery.
  • Patients participating in the acute phase of a pulmonary rehabilitation program, i.e., who started rehabilitation \< 4 weeks prior to screening.
  • Diagnosis of α-1 anti-trypsin deficiency.
  • Ongoing treatment with oral for any indication.
  • Treatment with systemic medication for COPD such as oral corticosteroids or monoclonal antibodies in the 28 days prior to screening.
  • Heart failure Class III or IV.
  • Acute myocardial infarction \< 6 months from screening visit.
  • or stroke \< 6 months from screening visit.
  • Hospitalization for any CV or cerebrovascular event \< 6 months from screening visit.
  • Ongoing treatment for cancer.
  • Other conditions that by the investigator's judgment cause remaining to be less than a year.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Intervention - treatment guided by digital tool

    Intervention guided by the digital tool

    Other: Guidance of the treating physician by a digital tool

Interventions

  • OtherGuidance of the treating physician by a digital tool

    The intervention is that the treating physician will be guided by a digital tool describing treatment recommendations for COPD. The choice of treatment will be made by the investigator, based on his or her clinical judgment supplemented with support from the educational tool. All participating patients in the study will be treated by a physician that uses the tool.

06

What researchers measure

Primary outcomes

  1. CAT score

    Change in COPD assessment test (CAT) score

    Time frame: 8 weeks

Secondary outcomes

  1. mMRC

    Change in mMRC (modified medical research council) score

    Time frame: 8 weeks

  2. Walking distance

    Change in walking distance on a 6 minute walk test

    Time frame: 8 weeks

07

Study locations

1 site
  • Näsets läkargrupp, Prima Vård AB
    Höllviken, 23651, Sweden
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Oct 2026, 6 months.

Of 1,097 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 6 months is below that.

Counting every sponsor, half of 1,185 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartActual
Mar 3, 2026
Primary completionActual
Oct 1, 2026
CompletionActual
Oct 1, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940608
Lead sponsor
Prima Vard AB
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Mar 3, 2026
Primary completion
Oct 1, 2026
Completion
Oct 1, 2026
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion